Ann: DAYBUE net sales US$87.1 million in Q4 2023, page-72

I listened to the earnings call and have revisited it a second time. Earnings guidance for Q1 24 are $76-82 million US. There was a lot of talk about "seasonality" and January being a poor month for both new patients and script refills and also some minor issues with insurance renewals for new calendar year. Most of this was due to January holidays and clinic visits at centres of excellence being reduced or not open at all. They were at pains to point out that February had seen a big uptick that had brought sales back in line with end of 2023 expectations. Given $76-82 million is a step back from Q4 2023 numbers I presume this is 1. Where Culper got their ammunition from and 2. Why Acadia felt necessary to give full year 2024 guidance to demonstrate it is not the start of a pattern/decline in sales.